A Phase Ib/II Study of Novel Combination Therapy in Metastatic TNBC
Recruiting Phase 1 NCT06959537
Study Description
A Study of Low-Dose Cyclophosphamide Combined with Axatilimab and Retifanlimab in Treating Metastatic Triple Negative Breast Cancer
Study Details
- Registry ID:
- NCT06959537
- Conditions:
- Breast Cancer
- Phase:
- Phase 1
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.